EN | TR
E-ISSN: 2651-2661 ISSN: 2651-2653
Evaluation of the relationship between kidney stone formation and intestinal inflammation in patients with ankylosing spondylitis
PDF
Cite
Share
Request
Original Article
VOLUME: 13 ISSUE: 1
P: 17-21
April 2021

Evaluation of the relationship between kidney stone formation and intestinal inflammation in patients with ankylosing spondylitis

J Turk Soc Rheumatol 2021;13(1):17-21
DOI: 10.4274/raed.galenos.2021.52523
Hava Demirhan 1
Tuncer Temel 2
Nevbahar Akçar Değirmenci 3
Zeynep Küskü Kiraz 4
Şükrü Saygın Demir 4
Döndü Üsküdar Cansu 5
Cengiz Korkmaz 5
1. Eskişehir Osmangazi Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Eskişehir, Türkiye
2. Eskişehir Osmangazi Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Gastroenteroloji Bilim Dalı, Eskişehir, Türkiye
3. Eskişehir Osmangazi Üniversitesi Tıp Fakültesi, Radyoloji Anabilim Dalı, Eskişehir, Türkiye
4. Eskişehir Osmangazi Üniversitesi Tıp Fakültesi, Biyokimya Anabilim Dalı, Eskişehir, Türkiye
5. Eskişehir Osmangazi Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Eskişehir, Türkiye
No information available.
No information available
Received Date: 11.02.2021
Accepted Date: 05.03.2021
Publish Date: 29.04.2021
PDF
Cite
Share
Request

ABSTRACT

Objective:

Renal stone formation is one of the extra-articular manifestations of ankylosing spondylitis (AS). In these study, it is investigated whether there is a relationship between renal stone formation and intestinal inflammation in AS patients.

Methods:

Patients meeting the 1984 Modified New York criteria for AS were included in the study. Calprotectin levels, an indirect indicator of intestinal inflammation, were measured in each patient. Colonoscopy and, if necessary, colonoscopic biopsy were performed in patients with calprotectin level >70 υg/g. AS patients who received infliximab or adalimumab were excluded from the study. The use of non-steroidal anti-inflammatory drugs was discontinued at least 6 weeks ago.

Results:

Ninety AS patients (M: 57; F: 33) (renal stone +: 26; renal stone -: 64) were included in the study. The mean age of the patients was 43±10.9 years; the mean age at diagnosis was 33±10 years and the diagnosis delay was 6.2±5 years. Calprotectin level was higher in 3 patients (11.5%) with renal stones (+), while calprotectin level was higher in 9 patients (14%) with renal stones (-). Histological evidence of intestinal inflammation was found in 5 (41%) of 12 patients with high calprotectin levels. These 5 patients did not have renal stones. In 3 patients with renal stone (+) and high calprotectin levels, no microscopic signs of inflammation in the intestine were observed.

Conclusion:

No relationship was found between fecal calprotectin level and the presence of renal stones. Serial calprotectin measurement studies with a much higher number of patients, excluding variables that may have a role in the intestinal microenvironment, will give much more reliable results in this regard.

References

1
Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61(Suppl 3):8-18.
2
El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 2011;22:554-60.
3
Sipponen T Savilahti E, Kolho KI, et al. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activityindex and endoscopic findings. Inflamm Bowel Dis 2008;14:40-6.
4
Henderson P, Casey A, Lawrence SJ, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatricinflammatory bowel disease. Am J Gastroenterol 2012;107:941-9.
5
Speca S, Dubuquoy L. Chronic bowel inflammation and inflammatory joint disease: pathophysiology. Joint Bone Spine 2017;84:417-20.
6
Klingberg E, Strid H, Stahl A, et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther 2017;19:21.
7
Korkmaz C, Ozcan A, Akcar N. Increased frequency of ultrasonographic findings suggestive of renal stones in patients with ankylosing spondylitis. Clin Exp Rheumatol 2005;23:389-92.
8
Canales BK, Leonard SM, Singh JA, et al. Spondyloarthropathy: an independent risk factor for kidney stones. J Endourol 2006;20:542-6.
9
Lui NL, Carty A, Haroon N, Shen H, Cook RJ, Inman RD.  Clinical correlates of urolithiasis in ankylosing spondylitis. J Rheumatol 2011;38:1953-6.
10
Gönüllü E, Bilge NŞY, Cansu DU, et al. Risk factors for urolithiasis in patients with ankylosing spondylitis: a prospective case-control study. Urolithiasis 2017;45:353-7.
11
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
12
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
13
Korkmaz C, Cansu DU, Sayer JA. Urolithiasis as an extraarticular manifestation of ankylosing spondylitis. Rheumatol Int 2017;37:1949-56.
14
Gaspar SR, Mendonça T, Oliveira P, Oliveira T, Dias J, Lopes T. Urolithiasis and crohn’s disease. Urol Ann 2016;8:297-304.
15
Turina MC, Sieper J, Yeremenko N, et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 2014;73:1746-8.
16
Matzkies FG, Targan SR, Berel D, et al. Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther 2012;14:R261. doi: 10.1186/ar4106.
17
Simioni J, Skare TL, Campos APB, et al. Fecal calprotectin, gut ınflammation and spondyloarthritis. Arch Med Res 2019;50:41-6.
18
Fulgham PF, Assimos DG, Pearle MS, Preminger GM. Clinical effectiveness protocols for imaging in the management of ureteral calculous disease: AUA technology assessment. J Urol  2013;189:1203-13.